Trump is right to investigate Germany — and he shouldn’t stop there

The Trump administration just launched a “Section 301” investigation into Germany’s pharmaceutical pricing practices. The move begins a process to address foreign free-riding by one of the world’s largest economies — and helps advance the broader goal of ensuring wealthy countries pay their fair share for global innovation. Patients in the United States, Germany, and […]

Read it at Washington Examiner ↗

← Front page